You are on page 1of 2

Cell Line Development Services Global Market

–Forecast to 2025

Cell line development Services Global Market estimated to be $1,214.7 million
by 2025

IQ4I Research & Consultancy published a new report on “Cell Line Development
Services Global Market – Forecast To 2025” This report analyzes and studies the overall
market, major Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-
Pacific and Rest of the World

The cell line development service market is expected to grow at double digit CAGR to reach
$1,214.7 million by 2025. Increasing demand for biologics and biosimilars, growing incidence
rate of oncology and immunological disorder and growth in research activities related to the
diseases are driving the market. Technological improvements in development,
manufacturing, screening technologies and assays are giving immense growth opportunity
for the market. However, complexities in development of stable cell lines and high risk of
contamination due to complex purification methods are restraining the market. Furthermore,
stringent and complex regulations and high cost and technical requirement to adhere with
accreditations such as GMP are posing threat to the industry.

Cell lines are essential for a wide range of applications including gene function studies, drug
discovery assays, the production of biotherapeutics and diagnostics. The application for cell
lines includes research, bioproduction and diagnostics. Among research, cell lines are used
for studying disease, screening, cell-based assays are used during discovery phase and
preclinical development. Cell lines are used to produce a wide range of biotherapeutics
including vaccine, recombinant proteins that include peptides, cytokines, hormones and
clotting factors, enzymes and monoclonal antibodies.

Biotherapeutics including monoclonal antibodies, peptides, recombinant proteins, vaccines,
blood related products are produced in a wide variety of platforms, including non-mammalian
expression systems (bacterial, yeast, plant and insect) and mammalian expression systems
(including human cell lines). However, the most appropriate expression system to be used
is dependent on the type of biopharmaceutical to be produced. Microbial systems are used
for producing relatively simple recombinant proteins such as insulin or antibody fragments.
They are attractive due to their low cost and high productivity. E. coli and S. cerevisiae are
the most commonly used systems. However, many biopharmaceuticals including MABs,
highly glycosylated proteins or recombinant proteins are large and complex, mammalian cell
lines are the most preferred platform used for manufacturing them. Post-translational
modifications including glycosylation, carboxylation, hydroxylation, sulphation, amidation are
a significant factor to select the type of cells to be used. Among them, glycosylation is the

IQ4I Research & Consultancy Pvt. Ltd. Page 1
Cell Line Development Services Global Market

–Forecast to 2025

most common modification. Mammalian expression system commanded the largest revenue
of the global cell line development services market, by expression system in 2016. The most
common mammalian cell cultures used for production of biopharmaceuticals include
Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK21) cells and murine
myeloma cells (NS0 and Sp2/0).

The cell line development services global market was estimated region wise, by type of cell
lines expression systems, by cell types and by application. This report also contains cost
analysis for various cell line development services. Key developments such as
collaborations, acquisitions, new launches, partnerships and expansions were reported and

• In depth assessment of all segments and sub segments of cell line development
services global market

• Regional analysis of cell line development services global market

• Market dynamics for cell line development services global market

• Cost analysis of different cell line development services and cell based assays

• Cell line type used in approved biologics (2012-2016) and analysis based on type of

• Comparison matrix of various key players with cell line development capabilities

IQ4I Research & Consultancy Pvt. Ltd. Page 2